Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy *
暂无分享,去创建一个
William M. Lee | W. M. Lee | K. K. Snow | M. Gale | H. Yuan | M. Jain | M. Gale, Jr. | H. Yuan | W. Lee | M. Jain
[1] William M. Lee,et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. , 2008, The New England journal of medicine.
[2] J. Kao,et al. The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. , 2008, Journal of hepatology.
[3] Zekuan Xu,et al. Comparative Analysis of Nearly Full-Length Hepatitis C Virus Quasispecies from Patients Experiencing Viral Breakthrough during Antiviral Therapy: Clustered Mutations in Three Functional Genes, E2, NS2, and NS5a , 2008, Journal of Virology.
[4] J. Pawlotsky,et al. NS5A sequences of hepatitis C virus genotype 1 and interferon resistance: where are we? , 2008, The Journal of infectious diseases.
[5] William M. Lee,et al. Nonresponse to Treatment for Hepatitis C , 2008, Drugs.
[6] William M. Lee,et al. Nonresponse to treatment for hepatitis C: current management strategies. , 2008, Drugs.
[7] C. Rice,et al. Identification of Residues Required for RNA Replication in Domains II and III of the Hepatitis C Virus NS5A Protein , 2007, Journal of Virology.
[8] A. Alberti,et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin. , 2007, The Journal of infectious diseases.
[9] Milton W. Taylor,et al. Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy , 2007, Journal of Virology.
[10] William M. Lee,et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. , 2007, Gastroenterology.
[11] G. Deléage,et al. Conserved Determinants for Membrane Association of Nonstructural Protein 5A fromHepatitis C Virus and Related Viruses , 2006, Journal of Virology.
[12] William M. Lee,et al. HCV RNA detection by TMA during the hepatitis C antiviral long‐term treatment against cirrhosis (Halt‐C) trial , 2006, Hepatology.
[13] M. Gale,et al. Evasion of intracellular host defence by hepatitis C virus , 2005, Nature.
[14] C. Walker,et al. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? , 2005, Journal of hepatology.
[15] William M. Lee,et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. , 2004, Controlled clinical trials.
[16] F. Zoulim,et al. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon–ribavirin therapy , 2004, Journal of medical virology.
[17] Mark Harris,et al. Hepatitis C virus NS5A: tales of a promiscuous protein. , 2004, The Journal of general virology.
[18] C. Rice,et al. Insertion of Green Fluorescent Protein into Nonstructural Protein 5A Allows Direct Visualization of Functional Hepatitis C Virus Replication Complexes , 2004, Journal of Virology.
[19] William M. Lee,et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.
[20] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[21] S. Chou,et al. Analysis of Sequence Configurations of the ISDR, PKR-Binding Domain, and V3 Region as Predictors of Response to Induction Interferon-α and Ribavirin Therapy in Chronic Hepatitis C Infection , 2002, Digestive Diseases and Sciences.
[22] C. Pasquier,et al. Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha. , 2003, The Journal of infectious diseases.
[23] T. Berg,et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy , 2002, Hepatology.
[24] William M. Lee,et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.
[25] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[26] M. Katze,et al. Subversion of Cell Signaling Pathways by Hepatitis C Virus Nonstructural 5A Protein via Interaction with Grb2 and P85 Phosphatidylinositol 3-Kinase , 2002, Journal of Virology.
[27] Angelo Balestrieri,et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[29] L. Beretta,et al. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR‐independent manner , 2001, Hepatology.
[30] M. Katze,et al. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. , 2001, Virology.
[31] N. Ishimura,et al. Co‐infection by serologically‐silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down‐regulation of type‐I interferon receptor gene expression in the liver , 2001, Journal of medical virology.
[32] S. Ray,et al. Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy , 2000, Journal of Virology.
[33] H J Alter,et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.
[34] H. Thomas,et al. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. , 1999, Gastroenterology.
[35] D. R. Taylor,et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.
[36] M. Katze,et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Yanagi,et al. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients , 1998, Journal of medical virology.
[38] Michael G. Katze,et al. Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation , 1998, Molecular and Cellular Biology.
[39] O. Jaillon,et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. , 1998, The Journal of general virology.
[40] J. Mullins,et al. Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection , 1998, Journal of Virology.
[41] S. Zeuzem,et al. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa , 1997, Hepatology.
[42] N Enomoto,et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.